Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 + CD22
- Development stage
- Unknown
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Parenteral
01
Overview
CD19 + CD22 (Senl_19+22) is an investigational dual-targeted chimeric antigen receptor T-cell (CAR-T) therapy developed by Hebei Senlang Biotechnology. This cell therapy is engineered to simultaneously target CD19 and CD22, two proteins frequently expressed on the surface of B-cell malignancies. By utilizing a dual-targeting approach, the therapy aims to mitigate the risk of antigen escape, which is a common mechanism of resistance and relapse in patients treated with single-target CAR-T products. The therapy is primarily being evaluated in early-phase clinical trials for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and adult populations, as well as other B-cell non-Hodgkin lymphomas.
- Other names
- CD19/CD22 dual-targeted CAR-TCD19+CD22 CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19 + CD22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 + CD22.